Quick Answer
Taysha Gene Therapies, Inc. reported Total Revenue of $9.77 million for fiscal year 2025.
Taysha Gene Therapies, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $9.77M | +17.3% |
| 2024 | $8.33M | -46.1% |
| 2023 | $15.45M | +517.5% |
| 2022 | $2.50M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | -100.0% | -100.0% |
| June 30, 2025 | $1.99M | +78.6% | -13.7% |
| March 31, 2025 | $2.30M | -32.5% | +28.7% |
| September 30, 2024 | $1.79M | -62.3% | +60.8% |
| June 30, 2024 | $1.11M | -53.6% | -67.4% |
| March 31, 2024 | $3.41M | -27.5% | -28.1% |
| September 30, 2023 | $4.75M | — | +98.2% |
| June 30, 2023 | $2.40M | — | -49.1% |
- Taysha Gene Therapies, Inc. showed an increase of +17.3% in Total Revenue compared to the prior fiscal year.
- Over the 2022–2025 period, Taysha Gene Therapies, Inc.’s total revenue has grown by 290.6% (from $2.50 million to $9.77 million).
- The most recent figure is from Taysha Gene Therapies, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: